Challenges in Diagnosis of Melanoma from the Perspective of a Pathologist
Main Article Content
Abstract
Introduction: Melanoma is an aggressive melanocytic neoplasm with a continuously increasing incidence worldwide. Vast majority of melanoma arises from skin whereas a small subset of melanoma can arise as a primary malignancy of mucosal membranes. Gastrointestinal (GI) melanoma is usually metastatic in origin whereas primary GI melanomas are extremely rare. Anorectal Melanoma comprises of 1/% of all malignant neoplasms of this area. About 70% of these lesions are pigmented whereas 30% of them are amelanotic. Upto 25% of the patients with melanoma develops recurrent disease locally or in regional lymph nodes.
Materials And Methods: This is a prospective study conducted in a tertiary care hospital comprising of six cases of Melanoma. We studied the cases according to their age, sex, clinical presentation, site, radiological findings, histopathological findings, immunohistochemical findings and treatment provided.
Results: This study comprises of six cases of Melanoma among which five cases are primary one case is recurrent. Among the five primary cases, four cases have GI origin (sigmoid colon, rectum, anal canal) one case originated from skin involving left foot. There is a single case of recurrent MM involving right inguinal lymph nodes with a history of primary MM in the right lower limb. The patients belong to the age group of 6th to 8th decade with male preponderance. Histopathological examination of formalin fixed paraffin tissue sections was done followed by Hematoxylin & Eosin and Immunohistochemical staining which confirmed the diagnosis of Melanoma.
Conclusion: Melanoma is an aggressive melanocytic neoplasm that carries a poor prognosis. It commonly involves skin. Its occurrence in GI tract is rare in which primary lesions are exceedingly unusual. Diagnosis and Treatment require multidisciplinary team approach with surgery remaining as a cornerstone of treatment.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Kalyan Saginala, Adam Barsouk, John Sukumar Aluru, Prashanth Rawla, Alexander Barsouk; Epidemiology of Melanoma, Med Sci (Basel). 2021 Dec; 9(4): 63. Published online 2021 Oct 20. doi: 10.3390/medsci9040063PMCID: PMC8544364
II. KhalidU, SaleemT, ImamAM, KhanMR. Pathogenesis, diagnosis and management of primary melanoma of the colon. WorldJSurgOncol2011;9:14.
III. BishopKD,OlszewskiAJ.Epidemiologyandsurvivaloutcome s of ocular and mucosal melanomas: a population based analysis. IntJCancer2014 ; 134:2961–71.
IV. CheungMC,PerezEA,MolinaMA,JinX,GutierrezJC,Frances chiD,etal.Defining the role of surgery for primary gastrointestinal tract melanoma. JGastrointestSurg2008;12:731–8.
V. H. Menon, R.R. Patel, T.R. Cushman, A. Amini, S.N. Seyedin, A.C. Adams, et al., Management and outcomes of primary anorectal melanoma in the United States, Future Oncol. 16 (8) (2020) 329–338.
VI. Husain, Musharraf; Rashid, Tajamul; Ahmad, Mir Mujtaba; Hassan, Mohammad Jaseem1,#. Anorectal malignant amelanotic melanoma: Report of a rare aggressive primary tumor. Journal of Cancer Research and Therapeutics 18(1):p 249-252, Jan–Mar 2022. |
DOI: 10.4103/jcrt.JCRT_461_20
VII. Solaz Moreno E, Vallalta Morales M, Silla Búrdalo G, Cervera Miguel JI,Díaz Beveridge R, Rayón Martín JM. Primary melanoma of the rectum:An infrequent neoplasia with an atypical presentation. Clin TranslOncol 2005;7:171 3.
VIII. Ballo MT, Gershenwald JE, Zagars GK, Lee JE, Mansfield PF, Strom EA,et al. Sphincter sparing local excision and adjuvant radiation for anal rectal melanoma.J Clin Oncol 2002;20:4555 8.
IX. Brady MS, Kavolius JP, Quan SH. Anorectal melanoma.A 64-year experience at Memorial SloanKetteringCancerCenter.DisColonRectum. 1995;38:146-51,doi:10.1007/BF02052442.
X. David AW, Perakath B. Management of anorectal melanomas: a 10-year review. Trop Gastroenterol. 2007;28:76-8.
XI. Stroh C, Manger T. Primary amelanotic anorectal melanoma-a case report. Zentralbl Chir. 2007;132:560-3,doi: 10.1055/s-2007-981393.
XII. Ottensmeier, C., Gore, M. Survival from melanoma of the skin in England and Wales up to 2001. Br J Cancer 99 (Suppl 1), S50– S52(2008).https://doi.org/10.1038/sj.bjc.6604586
XIII. Juzeniene A, Baturaite Z, Moan J, et al. Sun exposure and melanomas on sun-shielded and sun-exposed body areas. In: Reichrath J, editor. Sunlight, vitamin D and skin cancer. New York: Springer; 2013. p.1-15.
XIV. Gilchrest BA, Eller MS, Geller AC, et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999;340:1341-8.
XV. Liu Y, Sheikh MS. Melanoma: Molecular Pathogenesis and Therapeutic Management. Mol Cell Pharmacol. 2014;6(3):228. PMID: 25745537; PMCID: PMC4346328.
XVI. Karakousis CP, Balch CM, Urist MM, et al. Local recurrence in malignant melanoma: long-term results of the multi institutional randomized surgical trial. Ann Surg Oncol. 1996;3(5):446– 52.
XVII. Francken AB, Accortt NA, Shaw HM, et al. Prognosis and determinants of outcome following locoregional or distant recurrence in patients with cutaneous melanoma. Ann Surg Oncol. 2008;15(5): 1476–84.
XVIII. YiNH, LeeJW, LeeSH, KimJH, JeeSR, SeolSY. Primary malignant melanoma without melanosis of the colon.IntestRes2019;17:561–4.
XIX. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo HJ, Harrison R. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol. 2000 Mar;7(2):87-97. doi: 10.1007/s10434-000-0087-9. PMID: 10761786.
XX. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol.2001;19(16):3622–34.
XXI. Xie, J., Dai, G. & Wu, Y. Primary colonic melanoma: a rare entity. World J Surg Onc 20, 256 (2022). https://doi.org/10.1186/s12957-022-02721-z
XXII. XieJ,DaiG,WuY.Primary colonic melanoma :a rare entity.World J Surg Oncol2022;20:256.
XXIII. K. M. Bullard, T. M. Tuttle, D. A. Rothenberger et al., “Surgical therapy for anorectal melanoma,” Journal of the American College of Surgeons, vol. 196, no. 2, pp. 206–211, 2003.
XXIV. Podnos YD, Tsai NC, Smith D, Ellenhorn JD. Factors affecting survival in patients with anal melanoma.Am Surg. 2006;72:917-20.
XXV. Li Z, Šandera P, Beer M, Weber M. A rare case of recurrent primary anorectal melanoma emphasizing the importance of postoperative follow-ups. BMC Surg. 2020 Apr 7;20(1):68. doi: 10.1186/s12893-020-00727-6. PMID: 32264858; PMCID: PMC7140585.
XXVI. Ranjith S sivaranjith.j@gmail.com, Muralee M, Sajeed A, Arun PM, Cherian K, Nair CK, Augustine P, Anorectal melanoma: experience from a tertiary cancer care centre in South India; The Annals of The Royal College of Surgeons of England, 2017: 100(3); 185-189
XXVII. Hillenbrand A, Barth TF, Henne-Bruns D, Formentini A. Anorectal amelanotic melanoma. Colorectal Dis. 2008 Jul; 10(6): 612–5.
XXVIII. Cagir B, Whiteford MH, Topham A, Rakinic J, Fry RD. Changing epidemiology of anorectal melanoma. Dis Colon Rectum. 1999;42:1203 8.
XXIX. Taylor JP, Stem M, Yu D, Chen SY, Fang SH, Gearhart SL, et al. Treatment strategies and survival trends for anorectal melanoma: is it time for a change? World J Surg. 2019 Jul; 43(7): 1809– 19.
XXX. Chang JW , Yeh KY, Wang CH, Yang TS, Chiang HF, Wei FC et al. Malignant melanoma in Taiwan: A prognostic study of 181 cases. Melanoma Res 2004; 14: 537-41.
XXXI. Luk NM, Ho LC, Choi CL, Wong KH, Yu KH, Yeung WK: Clinicopathological features and prognostic factors of cutaneous melanoma among Hong Kong Chinese. Clin Exp Dermatol 2004; 29: 600-4.
XXXII. Roh MR, Kim J, Chung KY. Treatment and outcome of melanoma in acral location in Korean patients. Yonsei Med J 2010; 51(4); 562-8.
XXXIII. Bradford PT, Goldstein AM, McMaster ML, Tucker MA. Acral lentiginous melanoma incidence and survival pattern in the United States, 1986- 2005. Arch Dermatol. 2009; 145(4): 427-34.
XXXIV. Hudson DA, Krige JEJ, Stubbings H. Plantar melanoma: Results of treatment in three population Surgery 1998; 124(5): 877-82.
XXXV. Thompson JA. The revised American Joint Committee on Cancer staging system for melanoma. Semin Oncol 2002;29:361–9.
XXXVI. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO melanoma program experience [comment]. Ann Surg Oncol 2000;7:469–74.
XXXVII. Clary BM, Brady MS, Lewis JJ, Coit DG. Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001;233:250–8.
XXXVIII. Leong SP. The role of sentinel lymph nodes in malignant melanoma. Surg Clin North Am 2000;80:1741–57.
XXXIX. Badgwell B, Xing Y, Gershenwald JE, et al. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007;14(10):2867–75.
XL. Khan N, Khan MK, Almasan A, et al. The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys. 2011;80(3):645–54.
XLI. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589–97.
XLII. Agrawal S, Kane JM 3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph nodemetastatic melanoma. Cancer. 2009; 115(24):5836–44.